ERS Genomics and Medicines Discovery Catapult sign CRISPR/Cas9 license agreement

Partnership provides Medicines Discovery Catapult access to CRISPR gene editing technology across a broad range of drug discovery applications

Dublin, Ireland, and Cheshire, UK, 04 September 2024: ERS Genomics Limited (‘ERS’), the

CRISPR licensing Company, and Medicines Discovery Catapult (‘MDC’), an independent, not-for-

profit drug discovery innovation centre, have signed a non-exclusive commercial-use CRISPR license

agreement. The partnership combines ERS’s CRISPR/Cas9 patent portfolio with MDC’s world-class

expertise and technology.

MDC and its partners will benefit from access to ERS’ entire CRISPR/Cas9 portfolio – the

foundational CRISPR/Cas9 intellectual property held by Dr. Emmanuelle Charpentier. This will extend

MDC’s ability to provide breakthrough products and services that help de-risk drug discovery, drive

sector productivity and attract investment.

The agreement adds gene editing to MDC’s already strong research and commercial capabilities in

cellular science and biomarkers. MDC and ERS believe the partnership will lead to the development

of unique drug discovery tools and unlock insights that will drive faster, more effective drug discovery

research in the UK and beyond.

Professor Chris Molloy, CEO of Medicines Discovery Catapult, commented: “At MDC, we are

always looking for the right partnerships to drive innovation across our community, helping them bring

medicines to market faster for patient benefit. This agreement with ERS Genomics offers huge

potential for entrepreneurial scientists. By using the CRISPR/Cas9 portfolio with our world-class

expertise and technologies, we can deliver more breakthroughs together.”

John E Milad, CEO, ERS Genomics, said: “We welcome MDC to our family of licensees. Their

extensive network of partners and collaborators across the private and public sectors, including

CROs, universities, research institutes, and the NHS, will continue to widen access to CRISPR/Cas9

in drug discovery.”

ERS Genomics provides licensing to CRISPR/Cas9 technology for companies interested in pursuing

its use in their commercial programs. Comprising 100+ patents globally, ERS’ portfolio encompasses

CRISPR/Cas9 usage in all cells, including bacteria, archaea, yeasts, and algae. ERS Genomics

licenses these patents via its direct license from Emmanuelle Charpentier and now has nearly 150

licenses in place worldwide.